Jingjing Jiang

Company: Revolution Medicines

Job title: Senior Director, Translational Research

Seminars:

Combination Therapy to Outsmart RASAddicted Cancer – Informing Clinical Strategy with Preclinical Modeling 11:45 am

Identify biomarkers that can help direct the “right combination regimen” to the “right patients” Define upfront combination regimens that can prevent/ delay emergent resistance mechanisms to RevMed RAS(ON) inhibitors Understand if/how we can translate learnings between distinct RAS mutations and cancer histotypesRead more

day: Translation Track - Day 1 am